RxDoctor Payments Data

Nora Chan, MD

Neurology · East Meadow, NYNPI 1073774725

Payments from drug & device makers

$74,201in general payments, 2019–2025

Across 274 payments — averaging $270.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MDD US Operations, LLC$51K
  • Amneal Pharmaceuticals LLC$10K
  • Kyowa Kirin, Inc.$5K
  • AbbVie$4K
  • Acadia Pharmaceuticals Inc$2K
  • Medtronic$231
  • plus $363 from 8 others

What the payments were for

  • Consulting fees$4,59812%
  • Speaking & faculty fees$26,04670%
  • Travel & lodging$4,35312%
  • Food & beverage$2,2776%
  • Education$330%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,201 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$334,497
Medicare patients
653
Services billed
20,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate51$354,658
GocovriAmantadine Hcl46$192,158
RytaryCarbidopa/Levodopa87$172,573
NeuproRotigotine70$109,664
XadagoSafinamide Mesylate49$104,063
NourianzIstradefylline22$95,165
IngrezzaValbenazine Tosylate12$93,640
Rasagiline Mesylate136$36,229
Carbidopa-LevodopaCarbidopa/Levodopa740$25,932
NuedextaDextromethorphan Hbr/Quinidine12$21,848
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone51$14,023
AmantadineAmantadine Hcl105$12,725
OngentysOpicapone11$11,933
Carbidopa20$9,829
Pramipexole ErPramipexole Di-Hcl21$9,417

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$2,404$354,65851 claims
MDD US Operations, LLCGocovri$51,292$192,15846 claims
Amneal Pharmaceuticals LLCRytary$10,304$172,57387 claims
Kyowa Kirin, Inc.Nourianz$5,350$95,16522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in East Meadow

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →